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Abstract
Rationale Reversal learning requires associative learning and
executive functioning to suppress non-adaptive responding.
Reversal-learning deficits are observed in e.g. schizophrenia
and obsessive-compulsive disorder and implicate neural cir-
cuitry including the orbitofrontal cortex (OFC). Serotonergic
function has been strongly linked to visual reversal learning in
humans and experimental animals but less is known about
which receptor subtypes are involved.
Objectives The objectives of the study were to test the effects
of systemic and intra-OFC 5-HT2C-receptor antagonism on vi-
sual reversal learning in rats and assess the psychological mech-
anisms underlying these effects within novel touchscreen
paradigms.
Methods In experiments 1–2, we used a novel 3-stimulus task
to investigate the effects of 5-HT2C-receptor antagonism through
SB 242084 (0.1, 0.5 and 1.0mg/kg i.p.) cross-site. Experiment 3
assessed the effects of SB 242084 in 2-choice reversal learning.
In experiment 4, we validated a novel touchscreen serial visual
reversal task suitable for neuropharmacological microinfusions
by baclofen-/muscimol-induced OFC inactivation. In experi-
ment 5, we tested the effect of intra-OFC SB 242084 (1.0 or
3.0 μg/side) on performance in this task.
Results In experiments 1–3, SB 242084 reduced early errors but
increased late errors to criterion. In experiment 5, intra-OFC SB
242084 reduced early errors without increasing late errors in a
reversal paradigm validated as OFC dependent (experiment 4).
Conclusion Intra-OFC 5-HT2C-receptor antagonism de-
creases perseveration in novel touchscreen reversal-learning
paradigms for the rat. Systemic 5-HT2C-receptor antagonism
additionally impairs late learning—a robust effect observed
cross-site and potentially linked to impulsivity. These conclu-
sions are discussed in terms of neural mechanisms underlying
reversal learning and their relevance to psychiatric disorders.
Keywords Reversal learning . SB242084 . 5-HT2C receptor .
Orbitofrontal cortex . Rat
Introduction
Purposeful goal-directed behaviour requires flexible
responding to altered reinforcement contingences. In experi-
mental animals, such flexible responding is commonly
assessed using an appetitive, operant reversal-learning para-
digm in which initially learned reward contingencies are
switched. In order to successfully adapt and maximise the
amount of reward earned, subjects must not only learn to
suppress selection of the previously rewarded responses but
also to learn a novel association and to choose the previously
unrewarded (but now rewarded) option. In humans, impaired
cognitive flexibility has been observed across tasks in schizo-
phrenic patients (Tyson et al. 2004; Jazbec et al. 2007; Murray
et al. 2008; Ceaser et al. 2008; Pantelis et al. 2009), but
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reversal-learning deficits stand out as a core feature of first-
episode psychosis (Leeson et al. 2009). Despite a growing
literature on such impairment, the study of cognitive function
in the evaluation and development of novel antipsychotic
treatments has only recently received due focus (Moore
et al. 2013).
Much evidence implicates circuitry including the
orbitofrontal cortex (OFC), ventral (NAc) and dorsal striatum
(DStr) and the amygdala in reversal learning (Clark et al.
2004). In humans, the OFC has been shown to be activated
in fMRI studies of reversal learning (Hampshire and Owen
2006; Chamberlain et al. 2008). OFC-lesioned marmosets
show selective reversal deficits in an intra-dimensional/ex-
tra-dimensional set-shifting task (Dias et al. 1996). OFC le-
sion or inactivation has also repeatedly been found to impair
simple or serial reversal learning in rodents (Bussey et al.
1997; Schoenbaum et al. 2002; Chudasama and Robbins
2003; McAlonan and Brown 2003; Kim and Ragozzino
2005; Ghods-Sharifi et al. 2008; Bissonette et al. 2008;
Burke et al. 2009; Graybeal et al. 2011).
Reve r s a l l ea rn ing depends on se ro ton in (5 -
hydroxytrypamine or 5-HT) signalling. It is impaired follow-
ing acute tryptophan depletion in healthy human volunteers
(Park et al. 1994), and central 5-HT depletion in experimental
animals retards go/no-go reversal (Masaki et al. 2006), bowl-
digging reversal (Lapiz-Bluhm et al. 2009) and probabilistic
reversal learning in the rat (Bari et al. 2010). Increasing 5-HT
levels through pharmacological or genetic inactivation of the
5-HT transporter, in contrast, improves performance in visual
reversal (Brigman et al. 2010) and serial spatial reversal learn-
ing (Barlow et al. 2015). These effects may be related to altered
activity at 5-HT receptors specifically within the OFC. OFC-
selective 5-HT depletion retards serial visual reversal learning
in the marmoset (Clarke et al. 2004; Clarke et al. 2005; Clarke
et al. 2007) while OFC 5-HT markers have been found to cor-
relate with reversal performance in the rat (Masaki et al. 2006;
Barlow et al. 2015). Furthermore, systemic (Boulougouris et al.
2008; Nilsson et al. 2012) or OFC-specific (Boulougouris and
Robbins 2010) antagonism of the 5-HT2C receptor (5-HT2CR)
through SB 242084 can improve spatial reversal-learning per-
formance in rodents, whereas blockade of the 5-HT2A receptor,
in contrast, impairs reversal learning.
These findings may be relevant for reversal-learning im-
pairment associated with schizophrenia (Leeson et al. 2009):
5-HT levels in schizophrenic patients have been shown to
correlate with cortical atrophy (Van Kammen et al. 1985),
severity of cognitive impairment (Powchik et al. 1998),
hypofrontality during tests of cognitive flexibility
(Weinberger et al. 1988) and poor long-term clinical outcome
(Wieselgren and Lindström 1998). Furthermore, prefrontal
cortical aberrations in 5-HT2CR pre-mRNA editing (Sodhi
et al. 2001), 5-HT2CR mRNA levels (Castensson et al. 2005)
and 5-HT2R binding (Arora and Meltzer 1991; Powchik et al.
1998) have been reported in schizophrenic patients. Smaller
OFC volume has also been observed in schizophrenic patients
(Nakamura et al. 2008).
However, tests of reversal learning in human patients use
visual cues whereas preclinical testing in rodents generally
employs olfactory or spatial learning. Thus, touchscreen visu-
al reversal-learning paradigms have been developed for cog-
nitive testing that have been shown to be sensitive to OFC-
lesioning in both rats and mice (Bussey et al. 1997;
Chudasama and Robbins 2003; Graybeal et al. 2011) and
genetic manipulations in the mouse (Brigman et al. 2010;
Nithianantharajah et al. 2012).
The aim of the current study was to investigate the effects of
the 5-HT2CR antagonist, SB 242084, administered systemically
or intra-OFC during reversal learning using a series of novel
touchscreen tasks. In experiments 1 and 2, we developed a 3-
stimulus reversal paradigm for the rat previously used to test
object reversal learning in primates (Jentsch et al. 2002; Lee
et al. 2007) to assess the dose-dependent effects of SB 242084.
This specific paradigm was chosen to illuminate potential per-
severative reversal deficits: after contingency shifts (reversal) in
this paradigm, the presence of two CS− response options al-
lows the separation of errors according to perseverative re-
sponses (at the previous CS+) and non-perseverative responses
(at the ‘constant CS−’). To demonstrate the robustness and
reliability of the drug effects within the 3-stimulus reversal
paradigm, the initial findings conducted at an academic site
(Cambridge, UK) were replicated and extended by an industrial
partner (Lilly, UK) as part of the NEWMEDS initiative (http://
www.newmeds-europe.com). Experiment 3 investigated the
dose-dependent effects of systemic 5-HT2CR antagonism
through SB 242084 on a well-established two-choice visual
reversal-learning paradigm (Mar et al. 2013). In experiment 4,
in order to investigate the neuroanatomical substrate of the
observed effects, we developed a novel serial reversal-
learning task suitable for use in subregion-specific pharmaco-
logical studies exploring perseverative behaviour, and con-
firmed an OFC dependency on task performance through
baclofen/muscimol inactivation. In experiment 5, we assessed
the effect of intra-OFC 5-HT2CR antagonism on reversal learn-
ing by site-specific SB 242084 infusions in this novel task.
Methods and materials
Animals
Experiment 1 was performed at the academic partner
(University of Cambridge) and used 25 male Lister hooded rats
(Charles River, UK). Experiment 2 and experiment 3 were run
at the industrial partner (Eli Lilly) and used separate groups of
46 male Lister hooded rats (Harlan, UK). Animals in experi-
ments 1, 2 and 3 were housed in groups of four. Animals who
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failed to complete any stage of experiments 1–3 were excluded
from the analysis; see ‘Experimental design and statistical anal-
yses’, below. Following surgical implantation of guide cannu-
lae, the animals (Charles River, UK) in experiment 4 (N=10)
and experiment 5 (N=13) were single housed (experiments run
at University of Cambridge). Animals were food-deprived with
ad libitum access to water, and their body weights were main-
tained at about 85 % of their free-feeding weight. Animals were
fed each day 1 h after testing. Animals were weighed weekly or
each day during drug administration. Rats were maintained un-
der a 12-h light/dark cycle, with lights on at 7 PM (academic
partner) or 7 AM (industrial partner). The experiments were
conducted in accordance with the UK Animals (Scientific
Procedures) Act 1986.
Drugs
SB 242084 (Eli Lilly, Indianapolis, IN, USA) was initially
dissolved in PEG400 (Fisher Scientific, Loughborough, UK)
at 20 % of the final required volume, which was then made up
by 10 % (w/v) hydroxypropyl-beta-cyclodextrin (Sigma-
Aldrich, Poole, UK) in saline. Aliquots were frozen at −80 °C
in the quantities required for each test day. For systemic treat-
ment (experiments 1–3), SB 242084 was administered intra-
peritoneally (i.p.) at doses of 0 (vehicle), 0.1, 0.5 or 1.0 mg/kg
in a volume of 1 ml/kg 20 min prior to testing. For intra-OFC
microinfusions in experiment 5, SB 242084 was administered
at 0 (vehicle), 1 or 3μg/hemisphere immediately before testing.
Baclofen hydrochloride (Sigma-Aldrich) and muscimol
hydrobromide (Sigma-Aldrich) were dissolved separately in
sterile saline and prepared as a cocktail with each drug at a final
concentration of 1.0 mM (Zeeb et al. 2010).
Experiments 1–3: 2- and 3-stimulus reversal learning
A comparison of the different protocol parameters in experi-
ments 1–3 is shown in Table 2 and Supplementary Fig. 1. Rats
were pretrained to respond at a touchscreen in a behavioural
chamber (Med Associates, Georgia, VT, USA) to receive
45 mg sucrose reward pellets (Sandown Scientific,
Middlesex, UK). Full details of the pretraining procedure and
of the apparatus are provided in the Supplementary Material.
3-Stimulus discrimination and reversal learning For ex-
periment 1, a rodent 3-stimulus reversal task was employed,
based on prior, unpublished development work at the
University of Cambridge (Mar et al. 2012). Following trial
initiation, three different stimuli (one stimulus designated as
CS+, two stimuli designated as CS−s; Table 1) were presented
in three different response windows on the touchscreen. The
six possible spatial stimulus configurations occurred equal
number of times over every 30 trials but the same configura-
tion never recurred for more than two consecutive trials. If the
animal touched the CS+, all stimuli were removed from the
touchscreen and a reward pellet was delivered. If the animal
touched a CS−, all stimuli were removed, the houselight was
illuminated for a 5-s time-out period and an incorrect response
was recorded. After the animal collected the reward pellet
after a correct trial or after the 5-s time-out had elapsed fol-
lowing an incorrect trial, a 5-s ITI was initiated. After the ITI
had elapsed, the magazine-light began flashing at 1 Hz and a
new trial started when the animal nose poked in the magazine
(see Supplementary Fig. 1). The session ended after 45 min or
100 correct trials. The criterion for visual discrimination learn-
ing and all subsequent tests was ≥9 correct responses over 10
trials twice in one session using a rolling trial count. When
criterion was reached, animals were challenged with a reversal
on the following day.
Experiment 2 was designed to replicate the procedure from
experiment 1 but at the laboratory of the industrial partner (Eli
Lilly) rather than by the academic partner (University of
Cambridge). However, stimuli reward contingencies were
not counterbalanced in experiment 2 but counterbalanced in
experiment 1.
2-Stimulus discrimination and reversal learning The pro-
cedure of experiment 3 was adapted to parallel previous pro-
tocols investigating 5-HT2CR function and reversal learning
(Nilsson et al. 2012; Boulougouris et al. 2008; Boulougouris
and Robbins 2010). In the test phase, animals were required to
touch the stimulus within 10 s and the number of trials was
limited to 100 per session. After trial initiation, two stimuli
(one stimulus designated as CS+ and one stimulus designated
CS−) were presented in the two response windows. If the
animal touched the CS+, all stimuli were removed and a pellet
reward was delivered. If the animal touched the CS−, all stim-
uli were removed, the houselight was illuminated for a 5-s
time-out period and an incorrect response was recorded. If
the animal failed to respond within 10 s, all stimuli were re-
moved from the screen, the 5-s ITI was initiated and an omis-
sion was recorded. After the animal collected the reward pellet
after a correct trial or after the 5-s time-out had elapsed fol-
lowing an incorrect trial, a 5-s ITI was initiated. After the ITI
had elapsed, the magazine-light began flashing at 1 Hz. A new
trial started when the animal nose poked into the magazine
(see Supplementary Fig. 1). The session ended after 45 min or
100 trials. The criterion for discrimination and reversal learn-
ing was 9 correct responses over 10 trials twice in one session
using a rolling trial count. When criterion was reached, ani-
mals were challenged with a reversal on the next day.
Experiments 4–5: 2-stimulus serial visual reversal
learning
This paradigm was designed to allow rapid serial reversal
learning in the rat with consistent and high levels of
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perseverative behaviour after each contingency shift. Task pa-
rameters (e.g. stimuli, criteria for learning and the number of
retention sessions between reversals) were defined and
optimised in an initial cohort of rats that did not receive
intra-cerebral infusions (data not shown). The resulting proce-
dure, where each reversal phase typically took 3 days, is de-
scribed in the SupplementaryMaterial and briefly summarised
below.
2-Stimulus serial discrimination reversal learning Rats
were trained to respond at two stimuli simultaneously
presented on the screen, similar to experiment 3, above.
Thus, one stimulus (CS+) was associated with reward and
the other stimulus (CS−) with a houselight-signalled time-
out of 5 s. However, stimuli were horizontal and vertical
bars, to ensure rapid discrimination learning, and trials
were initiated by responding at a ‘start box’ at the bottom
centre of the screen. The start-box procedure was used to
ensure a central position of the animal before the choice
phase, based on prior development work by A.C.M. using
similar touchscreen procedures (Mar et al., 2012). No
masks were used for this paradigm.
The session ended after 150 rewards, 250 trials or 60 min,
whichever occurred first (Table 2). The ITI was set to 5 s and
the limited hold (stimulus presentation time and response win-
dow) was set to 10 s (see Supplementary Fig. 1). Criterion for
discrimination learning was set to 24 correct in a running
window of 30 trials. Once acquired, rats were given a retention
session using the same reward contingencies to confirm that
the rats had acquired the discrimination.
Following the discrimination and a retention session, the
contingencies reversed and the rats were required to respond
to the previous CS− until they reached the reversal criterion
(24/30). A retention session was included before each reversal
and after criterion was met. Additional reversals were per-
formed until the rats were able to reach the criterion within
three daily sessions.
Surgery The rats were surgically implanted with 22-GA
guide cannulae (PlasticsOne, Roanoke, VA, USA) under
isoflurane anaesthesia (anaesthesia was induced at 4 % and
maintained at 2 % isoflurane). The tooth bar was set to
−3.3 mm for flat skull position. Targets for lateral OFC guides
were AP +3.7, ML ±2.5 (from bregma) and DV −1.7 mm
(from dura). The guide cannulae were secured to the skull
using four metal screws and dental cement. Obturators that
ended flush with the guide cannulae were inserted and
protected with a dust cap.
Microinfusions After recovery from surgery (≥7 days), rats
received a retention session and were then reversed until cri-
terion (followed by another retention session) without drug
infusion to verify fast and stable serial reversal performance.
During this baseline reversal, rats were habituated to the infu-
sion procedure and received mock and vehicle infusions.
Injectors from PlasticsOne (28-GA) were extended 2 mm be-
low the guide for OFC infusions (−3.7 mm from dura).
Infusions were performed in a volume of 0.5 μl over 2 min.
The injector was left in place for 1 min before and after infu-
sion. During the infusion procedure, the rats were gently re-
strained or allowed to freely move on the lap of the
experimenter.
Following the baseline reversal, rats received intracerebral
infusions of baclofen/muscimol mix (experiment 4) or SB
242084 (experiment 5) across reversals according to a with-
in-subject, cross-over/Latin-square design. Microinfusions
were given each day of the reversal, i.e. from the session when
contingencies first shifted to the day that the rats reached cri-
terion on the task. Rats that reached criterion on the third day
thus received three infusions on consecutive days during that
reversal. Retention sessions (no infusions) were included the
day after criterion was met and again before the next reversal
started. Rats typically had 2 days without testing between
these retention sessions (i.e. a full reversal with retention ses-
sions and break was 7 days, during which the rats typically
Table 1 Comparison
of experimental parameters Experiments 1 and 2 Experiment 3 Experiment 4 and 5
3-stimulus reversal 2-stimulus reversal 2-stimulus serial reversal
Trials per session Unlimited 100 250
Correct per session 100 100 150
Incorrect per session Unlimited 100 250
Omissions NA >10 s >10 s
Time-out 5 s 5 s 5 s
Design Between-subjects Between-subjects Within-subjects
Criterion ≥9 correct over 10 trials
twice in one session
≥9 correct over 10 trials
twice in one session
≥24 correct over 30 trials
Experiment 1: vehicle N=16, 1.0 mg/kgN=9. Experiment 2: vehicle N=10, 0.1 mg/kgN=7, 0.5 mg/kgN=7,
1.0 mg/kgN=9. Experiment 3: vehicleN=12, 0.1 mg/kgN=11, 0.5 mg/kgN=12, 1.0 mg/kgN=11. Experiment 4
N=6. Experiment 5N=10
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received three infusions). In a few instances, rats did not reach
criterion during a retention session; these rats received a sec-
ond retention session on the following day and invariably
reached criterion on this additional session.
Histology At the end of the experiments, animals were given
a lethal dose of sodium pentobarbitone and perfused
transcardially with 0.01 M PBS followed by 4 % paraformal-
dehyde. The brains were removed, postfixed in 4 % parafor-
maldehyde for 24 h and preserved in 30 % sucrose in 0.01 M
PBS overnight. Coronal sections (60 μm) were stained with
cresyl violet and used to verify injector-tip placement inside
the lateral OFC according to a standard rat brain atlas (Paxinos
and Watson 1998).
Experimental design and statistical analyses
Experiments 1–3 These experiments employed between-
subject designs. Experiments 1 and 2 used a serial design with
new stimulus triplets presented in each new discrimination
phase (Table 1). After completing an initial three-choice dis-
crimination drug free, animals were matched for trials to cri-
terion and assigned to a drug dose for the first reversal.
Animals subsequently completed two more three-choice visu-
al discriminations followed by reversals. Animals were dosed
in reversal 1, reversal 2 and visual discrimination 3. Animals
completed visual discrimination 1, visual discrimination 2 and
reversal 3 drug free.
In Experiment 3, animals initially completed a two-choice
discrimination drug free and were subsequently matched for
trials to criterion and assigned to a drug dose for reversal
testing (Table 2). The stimuli used in experiment 1 were based
on previous reports showing that animals have minimal
spontaneous visual biases for this stimulus pair (Bussey
et al. 2008).
The primary dependent variables for experiments 1, 2 and 3
were trials and errors to criterion. In addition, we analysed
correct responses to criterion as well as response latency and
pellet-retrieval latency. Latency data from experiment 1 were
lost due to a computer malfunction. In the 3-stimulus discrim-
ination (experiments 1 and 2), incorrect responses were further
divided into responses towards the previous CS+ (‘previous
CS+’ errors) and responses towards the constant CS− (constant
CS− errors). In the reversal phases of experiment 1–3, incorrect
responses were additionally coded as early errors and late errors
corresponding to before and after animals had reached random
responding. Thus, early errors were the number of incorrect
responses made before achieving 33 % (≥3 correct responses
over 10 trials) twice in the 3-stimulus paradigm and the number
of incorrect responses made before achieving 50 % (≥5 correct
responses over 10 trials) twice in the 2-stimulus paradigm. Late
errors corresponded to errors made after reaching 33 and 50 %,
respectively. The data for the three procedures of experiments 1
and 2 where SB 242084 was administered were analysed by 3
(within-subjects: phase)×4 (between-subjects: drug dose)
mixed ANOVAs. The data for the reversal phase in experiment
3, as well as the third, drug-free reversal phase test in experi-
ments 1 and 2, were analysed by one-way between-subjects
ANOVAs with drug-dose group as the independent variable.
Significant interactions were followed by LSD post-hoc com-
parisons versus vehicle.
Animals who failed to complete any stage of experiments
1–3 were excluded from the analysis (experiment 1: vehicle
N=2, 1.0 mg/kgN=2; experiment 2: vehicle N=1, 0.1 mg/kg
N=3, 0.5 mg/kgN=3, 1.0 mg/kgN=3; experiment 3: vehicle
N=0, 0.1 mg/kgN=1, 0.5 mg/kgN=0, 1.0 mg/kgN=1).
Table 2 Stimulus-reward contingencies
Stimulus-reinforcement contingencies in 2-stimulus reversal learning (Experiment 3), 3-stimulus reversal learning (Experiment 1 and 2) and serial
reversal learning (Experiment 4 and 5).
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Experiments 4–5 These experiments employed within-
subjects designs. Data from each reversal were collapsed over
days. Trial outcomes were next coded as perseverative, ran-
dom or learning depending on performance over 30 trials and
based on binomial distribution probabilities. Thus, any 30-
trial bin in which the rat displayed a significant bias towards
the previously correct stimulus (<11 correct) was coded as
perseverative, whereas any 30-trial bin in which the rat
displayed a significant bias towards the currently correct stim-
ulus (>19 correct) was coded as learning. Bins were coded as
perseverative or learning wherever they occurred during the
session, meaning that rats technically could shift multiple
times between perseverative and random, and random and
learning phases. In experiments 1–5, data from after criterion
was reached were excluded from analysis.
The primary dependent variables were trials, errors and
omissions in each phase (note that omissions only occurred
if the animals actively initiated a trial by touching the start
box). Latencies to respond at the stimuli (after initiating a trial)
and to collect reward pellets were additionally analysed.
Analysis of the data from the first cohort of rats (data not
shown) suggested that square-root transformation produced
normal distribution of scores for trials, incorrect responses
and omissions. Transformed data were analysed using two-
way repeated measures ANOVA, in a 2 (baclofen/muscimol
dose)×3 (phase) or in a 3 (SB 242084 dose)×3 (phase) de-
sign. Planned comparisons were performed for the effects of
both baclofen/muscimol inactivation and of SB 242084 on
perseverative performance. Percent correct responses on the
first day of reversal was analysed as an alternative measure of
early, perseverative performance, using one-way repeated-
measures ANOVA or paired t-test as appropriate. Similarly,
performance in 30-trial bins were analysed for the first 300
tr ials using two-way repeated-measures ANOVA
(Supplementary Fig. 2). For latency scores, median values
for the different doses for each subject were entered into
the statistical analysis. Animals that lost their cannulae
during the course of the experiment (experiment 4: N=3;
experiment 5: N=3), as well as animals with injector tips
outside the lateral OFC (experiment 4: N=1), were exclud-
ed from all analyses.
Results
Experiment 1—SB 242084 and 3-stimulus serial visual
reversal learning
SB 242084 had a main effect on trials to criterion (Fig. 1a; F1,
18=7.662, p=0.013); post hoc analysis revealed a significant
impairment on the second reversal (p=0.005) but not the first
reversal (p=0.055) or visual discrimination (p>0.10).
SB 242084 also had an effect on incorrect responses to
criterion (Fig. 1b; F1,18=8.370, p=0.001), with increased
number of errors in the first (p=0.026) and on the second
reversal (p=0.003) but not discrimination learning (p>0.10).
Previous CS+ errors were also affected by the SB 242084
dose (Fig. 1c; F1,18=5.086, p=0.037), with a significant in-
crease in the second reversal (p=0.004) but not the first rever-
sal (p=0.081) or the drug-free third reversal (p>0.10). SB
242084 increased constant CS− errors (Fig. 1d; main effect
of drug; F1,18=7.679, p=0.013) during both the first (p=
0.011) and second (p=0.006) reversals.
SB 242084 numerically reduced early errors but the effect
was not significant (Fig. 2b; F1,18=1.506, p>0.10). In con-
trast, late errors were significantly affected by the drug
(Fig. 2a; F1,18=6.774, p=0.018). SB 242084 increased late
errors during the first (p=0.028) and the second reversal (p=
0.003). On the last, drug-free reversal, no differences between
groups were observed (p>0.10).
Experiment 2—replication of SB 242084-induced effects
on 3-stimulus visual reversal learning in a partner
laboratory
SB 242084 decreased early errors but increased late errors
causing an overall increase in trials and incorrect re-
sponses to criterion on reversal learning (Figs. 1 and 2).
There were no effects of SB 242084 on visual discrimi-
nation learning. SB 242084 decreased stimulus response
latencies in both visual discrimination and reversal learn-
ing (Table 3).
On trials to criterion (Fig. 1e), there was a significant main
effects of test phase (F2,58=157.96, p<0.0001) and dose (F3,
29=5.124, p=0.006) and a significant dose×phase interaction
(F6,58=2.489, p=0.033); 0.1 mg/kg (p=0.035) and 1 mg/kg
(p=0.005) of SB 242084 increased trials to criterion in rever-
sal one, and 0.5 mg/kg (p=0.013) and 1 mg/kg (p=0.005) of
SB 242084 increased trials to criterion in reversal two. SB
242084 had no effect on trials to criterion in discrimination
learning (F3,29=0.761, p=0.525).
On incorrect responses to criterion (Fig. 1f), there was
significant main effects of test phase (F2,58=184.884,
p<0.0001) and dose (F3,29=5.448, p=0.004) and a signif-
icant dose×phase interaction (F6,58=2.783, p=0.019).
0.1 mg/kg (p=0.023) and 1 mg/kg (p=0.004) of SB
242084 increased incorrect responses in reversal one.
0.5 mg/kg (p=0.014) 1 mg/kg (p=0.003) of SB 242084
increased incorrect responses in reversal two. SB 242084
had no effect on incorrect responses in discrimination
learning (F3,29=0.772, p=0.519).
For previous CS+ errors (Fig. 1 g), there were significant
main effects of phase (F1,29=168.7, p<0.0001) and dose (F3,
29=4.12, p=0.015) but no dose×phase interaction (F3,29=
2.361, p=0.092). Animals made more previous CS+ errors
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in reversal 2 than in reversal 1. 0.5 mg/kg (p=0.013) and
1 mg/kg (p=0.005) of SB 242084 increased previous CS+
errors relative to vehicle treated controls.
For constant CS− errors (Fig. 1 h), there were significant
main effects of phase (F1,29=66.497, p<0.0001) and dose (F3,
29=3.086, p=0.043) but no significant dose×phase interaction
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Fig. 1 Effects of SB 242084 on
3-stimulus visual discrimination
and reversal learning in the rat at
the academic (experiment 1; a–d)
and industrial (experiment 2; e–h)
partners. In reversal learning, SB
242084 increased trials (a, e), in-
correct responses (b, f) ‘previous
CS+’ errors (c, g) and ‘constant
CS−’ errors (d, h) to criterion at
both the academic and industrial
sites. Stimulus-reward contingen-
cies were not counterbalanced in
experiment 2 but counterbalanced
in experiment 1. Asterisks denote
p<0.05 vs. vehicle (*p<0.05;
**p<0.01)
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(F3,29=2.791, p=0.058). Animals made more constant CS−
errors in reversal 2 than reversal 1. 0.5 mg/kg (p=0.024) and
1 mg/kg (p=0.01) of SB 242084 increased constant CS− er-
rors relative to vehicle treated controls.
For early errors (Fig. 2d), there was a significant effect of
reversal phase (F1,29=27.937, p<0.0001), dose (F3,29=3.075,
p=0.043) and dose×reversal phase interaction (F3,29=3.342,
p=0.033). 0.1 mg/kg (p=0.044) and 1 mg/kg (p=0.006) of
SB 242084 decreased early errors in reversal 1. On late errors
(Fig. 2c), there was a significant effect of reversal phase (F1,29=
104.286, p<0.0001) and dose (F3,29=6.406, p=0.002) with SB
242084 increasing late errors relative to vehicle treated con-
trols. Moreover, there was a significant effect of dose on trials
(F3,29=3.922, p=0.018), incorrect responses (F3,29=3.279, p=
0.035), late errors (F3,29=3.189, p=0.038) but not early errors
(F3,29=2.535, p=0.076) in the drug-free reversal 3.
In sum, SB 242084 dose dependently decreased early er-
rors but increased late errors in reversal learning without
affecting discrimination learning. SB 242084 also decreased
stimulius response latencies.
Experiment 3—SB 242084 and 2-stimulus visual reversal
learning
In 2-stimulus reversal learning (Fig. 3a–d) there were trends
for SB 242084 to decrease the number of early errors but
increase the number of late errors causing an overall increase
in the number of trials and incorrect responses to criterion. SB
242084 significantly decreased stimulus response times and
pellet retrieval latencies.
There was no significant effect of SB 242084 trials to cri-
terion (Fig 3a; F3,42=2.426, p=0.079), incorrect responses to
criterion (Fig. 3b; F3,42=1.485, p=0.232) omissions to crite-
rion (F3,42=0.901, p=0.449) or early errors (Fig. 3c; F3,42=
2.206, p=0.102). However, there were significant dose-linear
effects of SB 242084, with higher doses increasing trials to
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Fig. 2 Effects of SB 242084 on
early errors and late errors in 3-
stimulus reversal learning at the
academic (experiment 1; a, b) and
the industrial (experiment 2; c, d)
partners. SB 242084 increased
late errors in both laboratories (a,
c). SB 242084 decreased early
errors but the effect reached sig-
nificance only at the industrial site
(b, d). Stimulus-reward contin-
gencies were not counterbalanced
in experiment 2 but
counterbalanced in experiment 1.
Asterisks denote p<0.05 vs. ve-
hicle (*p<0.05; **p<0.01)
Table 3 Mean response latency and reinforcer retrieval latency in seconds (±SEM) in experiment 2
Reversal 1 Reversal 2 Discrimination 3 Reversal 3a
Dose Response Retrieval Response Retrieval Response Retrieval Response Retrieval
Vehicle 3.63±0.30 1.84±0.13 3.81±0.47 1.51±0.04 2.96±0.23 1.40±0.05 3.00±0.20 1.54±0.11
0.1 2.90±0.09 1.61±0.14* 2.81±0.24* 1.59±0.09 2.31±0.11* 1.33±0.06 3.28±0.41 1.43±0.05
0.5 3.26±0.38 1.56±0.09** 2.72±0.14* 1.55±0.12 2.65±0.31 1.34±0.08 3.73±0.23 1.67±0.19
1. 0 2.81±0.24* 1.47±0.10* 2.70±0.15* 1.71±0.14 2.27±0.18* 1.43±0.05 3.58±0.31 1.49±0.05
Asterisks denote significant difference from vehicle (*p<0.05; **p<0.01)
a Drug free
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criterion (F1,42=7.123, p=0.011) and decreasing early errors
(F1,42=5.823, p=0.020). There was a significant effect of SB
242084 on late errors to criterion (Fig. 3d; F3,42=2.916, p=
0.045) with 0.5 and 1 mg/kg of SB 242084 increasing the
number of errors in the late phase of learning (p≤0.025).
SB 242084 also decreased response and pellet retrieval
latencies (Table 4). There was a significant main effect of dose
on stimuli response latencies (F3,42=5.719, p=0.002), with all
doses decreasing the time taken to respond. There was also a
significant effect of dose on pellet retrieval latencies (F3,42=
3.831 p=0.016), with 0.5 and 1 mg/kg (p≤0.023) of SB
242084 decreasing the time taken for collection of pellet
reward.
Experiment 4—development of a touchscreen serial visual
reversal task and validation using intra-OFC
baclofen/muscimol infusions
In preliminary experiments (data not shown), optimal param-
eters for the serial visual reversal task (e.g. robust persevera-
tive responding across multiple reversals) were established
and defined as a running criterion of 24 correct/30 trials and
two (drug-free) retention sessions between reversals. These
parameters were then used throughout experiments 4 and 5.
Six rats had intact cannulae throughout the study and in-
jector tips inside the lateral OFC. Infusions of a baclofen/
muscimol cocktail into the lateral OFC impaired early perfor-
mance on the serial visual reversal task (Fig. 4a–d). After
baclofen/muscimol inactivation of the OFC, two-way repeat-
ed measures ANOVA revealed a significant main effect of
phase on trials (F2,10=5.507, p=0.024) and a non-significant
effect of drug (F1,5=5.382, p=0.068); no interaction was not-
ed (F2,10=1.988, p>0.10). Planned comparisons in the persev-
erative phase showed a trend for the effect of OFC inactivation
on perseverative trials (p=0.094). On the number of incorrect
responses (Fig. 4b), there was a main effect of phase (F2,10=
12.54, p=0.0019) and a non-significant trend for effect of
drug (F1,5=5.296, p=0.070) but no interaction (F2,10=2.058,
p>0.10). In a planned comparison of incorrect responses dur-
ing the perseverative phase, a non-significant trend of drug
was observed (p=0.077).
On omissions (Fig. 4c), there was an effect of phase (F2,
10=7.426, p=0.011), drug (F1,5=11.15, p=0.021) and a
phase×drug interaction (F2,10=8.133, p=0.008). Post hoc
tests revealed that baclofen/muscimol infusions increased the
number of omissions during the perseverative phase (p=
0.0002), but had no effect during the random or learning
phases. Baclofen/muscimol infusions reduced percent correct
responses on the first day of reversal (Fig. 4d; t5=3.126, p=
0.026). No significant effect was noted on either response
latency (paired t test, t5=1.711; p>0.10) or latency to collect
rewards (paired t test, t5<1, p>0.10; Table 5).
Experiment 5—intra-OFC infusions of SB 242084
in the serial visual reversal task
Ten rats had intact cannulae throughout the study and injector
tips inside the lateral OFC. SB 242084 locally infused into the
OFC-improved performance during the early, perseverative
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Fig. 3 Dose-dependent effects of SB 242084 on 2-stimulus reversal
learning in the rat. a Trials to criterion. No effect of dose but a significant
dose-linear effect. b Incorrect responses. No effect of dose. c Early errors.
No effect of dose but a significant dose linear effect. d Late errors.
Significant effect of dose as well as a dose linear effect. Broken line
represents mean discrimination learning performance. Asterisks denote
p<0.05 vs. vehicle (*p<0.05)
Table 4 Mean touch-screen response and reinforcer retrieval latencies
in seconds (±SEM) in experiment 3
Discriminationa Reversal
Dose Response Retrieval Response Retrieval
Vehicle 3.35±0.16 2.05±0.17 2.89±0.11 1.72±0.11
0.1 3.00±0.20 2.04±0.21 2.28±0.17** 1.49±0.10
0.5 3.12±0.17 2.00±0.14 2.27±0.13** 1.43±0.07*
1. 0 3.03±0.15 1.93±0.14 2.24±0.11** 1.31±0.06**
Asterisks denote significant difference from vehicle (*p<0.05;
**p<0.01)
a Drug free
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phase (Fig. 4e–h). In a two-way repeated-measures ANOVA,
there was a significant main effect of phase on trials (F2,18=
9.03, p=0.0019) but no effect of drug (F2,18=1.04, p>0.10) or
phase×drug interaction (F4,36=1.49, p>0.10). However,
planned comparisons in the perseverative phase showed a
reduced number of trials at 1 μg/side (p=0.046) and a trend
at 3 μg/side (p=0.070). On the number of incorrect responses
(Fig. 4f), there was a main effect of phase (F2,18=13.28, p=
0.0003) but no effect of drug (F2,18=1.215, p>0.10) or inter-
action (F4,36=1.811, p>0.10). In a planned comparison of
incorrect responses during the perseverative phase, SB
242084 reduced the number of errors at 1 μg/side (p=0.022)
and at 3 μg/side (p=0.042).
On omissions (Fig. 4 g), there was a main effect of phase
(F2,18=4.49, p=0.026) but no effect of drug (F2,18=1.83,
p>0.10) and no phase×drug interaction (F4,36<1, p>0.10).
Planned comparisons in the perseverative phaserevealed no
significant effect of SB 242084 infusions, but a trend at
1 μg/side (p=0.059). Intra-OFC infusions of SB 242084 did
not affect percent correct responses on the first day of reversal
(Fig. 4 h; F2,27<1, p>0.10). Likewise, no significant effect
was noted on either response latency (F1.809,16.28=1.107,
p>0.10) or latency to collect rewards (F1.694,13.55<1,
p>0.10); see Table 5.
Discussion
Systemic 5-HT2CR antagonism by SB 242084 improved per-
formance in the early stages of touchscreen-based visual re-
versal learning in the rat. This apparently cognitive-enhancing
dose-dependent effect was observed across two separate tasks
and reproduced following direct microinfusions of SB 242084
into the rat OFC, which has been previously implicated in
reversal learning.
Surprisingly, in view of these early improvements in rever-
sal learning and previously published data (Boulougouris et al.
2008; Nilsson et al. 2012), systemic SB 242084 additionally
impaired performances in the later stages of reversal learning,
thus causing an overall decrement in performance. This effect
was reproduced across paradigms and observed cross-site in
the laboratories of both academic and industrial partners of the
Fig. 4 Effects of pharmacological inactivation and intracerebral SB
242084 infusions on the touchscreen serial visual reversal task. a
Histological validation of baclofen/muscimol cohort. A total of six rats
had cannulae targeting the lateral OFC and received all infusions. b Effect
of pharmacological inactivation on total trials. c Effect of pharmacolog-
ical inactivation on omissions. Note that omissions are only possible after
the rats have initiated a trial by responding at the ‘start box’ (see Supple-
mentary Fig. 1). d Effect of pharmacological inactivation on percent
correct responses during the first reversal session (e) histological valida-
tion of OFC SB 242084 cohort. A total of 10 rats had cannulae targeting
the lateral OFC and received all infusions. f Effect of intra-OFC SB
242084 infusions on total trials across phases. g Effect of intra-OFC SB
242084 infusions on omissions. h Effect of intra-OFC SB 242084 on
percent correct during the first reversal session. Asterisks denote p<0.05
vs. vehicle (*p<0.05; ***p<0.001)
Table 5 Mean response latency and reinforcer retrieval latency in
seconds (±SEM) after micro-infusions in experiments 4 and 5
Baclofen/muscimol SB 242084
Dose Response Retrieval Dose Response Retrieval
Vehicle 0.72±0.03 1.17±0.20 Vehicle 1.10±0.12 0.79±0.10
1 mM 0.85±0.08 1.22±0.15 1 μg/side 1.14±0.10 0.86±0.15
3 μg/side 1.04±0.09 0.85±0.10
No significant effect of drug
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NEWMEDS collaboration. However, the detrimental effects
were not observed after OFC infusion suggesting that the early
improvement in reversal learning may depend on a selective
reduction in perseverative responding mediated by 5-HT2CRs
in the OFC.
This study has provided an innovative new suite of
methods for assessing visual reversal learning in the rat. We
adapted a 3-stimulus version previously used in primates to
further analyse the nature of the reversal-learning effects (ex-
periments 1 and 2). We also introduced a novel 2-stimulus
version suitable for within-subject neuropharmacological in-
vestigations that was validated to be dependent on OFC cir-
cuitry via baclofen/muscimol inactivation (experiment 4). The
discussion will focus on the desirability of replicating findings
across academic laboratories and the industrial setting and
evaluating the methodological innovations reported in this
study as well as the role of 5-HT inmodulating neural circuitry
underlying reversal learning and its possible clinical
implications.
Academic-industrial cross-site replication
There is an urgent need for replication of behavioural findings
following either genetic (Crabbe and Wahlsten 1999) or phar-
macological (Insel et al. 2013) manipulations in experimental
animals. We have addressed this objective by introducing ro-
dents (Bussey et al. 2012), which via the intermediaries of
computer-controlled touchscreen tasks have translational rel-
evance to human tests such as the CANTAB battery (Robbins
et al. 1994; Robbins et al. 1998). Visual reversal learning has
been shown to be readily translatable across species from
mouse to rat to non-human primate to human participants
(Keeler and Robbins 2012). Hitherto, the human and non-
human primate tests of reversal learning have used
computer-controlled touchscreen methods to study visual re-
versal whereas rodent versions have often employed olfactory
or other non-visual modalities. However, Chudasama and
Robbins (2003) did use similar methods to those in primates
when investigating the effects of OFCmanipulations on visual
reversal learning in the rat. The present study has developed
this methodology further by employing carefully chosen
visual stimuli that optimise rapid learning and also enable
serial reversal learning to be investigated sometimes with-
in the same test session. This new protocol has been dis-
tributed among several laboratories in the NEWMEDS
consortium, and in this report, we show that effects of
pharmacological manipulations can be readily replicated
and extended by this form of academic-industrial collab-
oration. The use of novel touchscreen tasks reported here
adds further translational value to previous results and
indicates that 5-HT2CR mechanisms play an important
role in visual reversal learning.
5-HT2CR antagonism improves early reversal learning:
neural substrates
The novel observation that 5-HT2CR antagonism can improve
aspects of visual reversal learning is in agreement with previ-
ous studies on spatial reversal. Thus, using a spatial, left-right
serial reversal paradigm in an operant chamber, systemic 5-
HT2CR antagonism also decreased early errors (Boulougouris
et al. 2008) and attenuated subchronic PCP-induced reversal-
learning impairments in rats (McLean et al. 2009). Decreased
activity at the 5-HT2CR through constitutive or pharmacolog-
ical inactivation also improved aspects of reversal learning in
mice (Nilsson et al. 2012; Nilsson et al. 2013). The improved
reversal learning following OFC 5-HT2CR antagonism is in
contrasts with the impaired reversal learning associated with
decreased 5-HT action as a whole through OFC 5-HT-
depletion in marmoset monkeys (Clarke et al. 2007) or as a
function of interindividual variations in OFC 5-HT markers in
the rat (Barlow et al. 2015).
An obvious interpretation of the reduction in early errors by
SB 242084 is that it reduces perseverative responding
(Boulougouris et al. 2008). However, in the present study,
we found no evidence of specific amelioration of stimulus-
perseveration responding using the novel 3-stimulus reversal
paradigm which has been suggested to distinguish between
effects on perseveration or more general learning (Jentsch
et al. 2002). Instead, SB 242084 had similar effects on both
constant CS− errors and previous CS+ errors. This could be in
line with the previous observation of Nilsson et al. (2012) that
systemic 5-HT2CR antagonism facilitated ‘learned non-re-
ward’ while the perseverative repetition of a previously rein-
forced choice was unaffected. In contrast, the impairment as-
sociated with 5,7-DHT lesion of the OFC in marmoset mon-
keys was selectively displayed when the animals were tested
for stimulus perseveration (Clarke et al. 2007).
In agreement with previous reports (Boulougouris and
Robbins 2010), the current data show that the ability of SB
242084 to improve aspects of reversal learning is related to its
effects in the OFC. The 5-HT2CR appears to have an inhibi-
tory function on neuronal activity within the prefrontal cortex;
these receptors are present on GABAergic, primarily
parvalbumin-containing, interneurons (Liu et al. 2007).
Furthermore, micro-iontophoretic application of non-
selective 5-HT2CR agonists suppresses firing rates in the
OFC or mPFC (El Mansari and Blier 1997; Bergqvist et al.
1999; Zghoul and Blier 2003). Increased OFC activity has
previously been linked with improved reversal learning
(O'Doherty et al. 2001), and thus, the observed improved re-
versal performance may result from SB 242084 potentiating
such activity in this area. In further support of this view, 5-
HT2CR antagonism elevates DA-dialysate levels in the PFC
(Millan et al. 1998; Gobert and Millan 1999; Gobert et al.
2000) and loss of 5-HT2CR function can cause glutamatergic
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supersensitivity at OFC AMPA receptors (Rueter et al. 2000).
Potentiation of AMPA-receptor transmission can have pro-
cognitive effects, including PFC-specific enhancements of
LTP-formation (Black 2005), improved reversal learning in
the bowl-digging procedure (Woolley et al. 2009) and attenu-
ation of the attentional set-shifting deficits produced by sub-
chronic PCP (Broberg et al. 2009). Thus, the observed im-
provement following OFC-specific SB 242084 infusions
may be related to decreased 5-HT2CR function potentiating
glutamatergic and dopaminergic signalling within the OFC.
One caveat in this context is that we did not observe a dose-
dependent effect of SB 242084 in the current experiment. This
might be related to the higher dose range employed here; it can
be speculated that full receptor occupancy is reached already
at the 1 μg/side dose or even that off-target effects counteract
the main effect on 5-HT2CR in the OFC at the 3 μg/side dose,
although the affinity of SB 242084 is more than 100-fold
higher for 5-HT2CR than for other receptors (Kennett et al.
1997).
5-HT2CR impairs late reversal performance: systemic
effects
Systemic SB 242084 was also found to impair overall reversal
learning by increasing the number of late errors to criterion.
This effect appears to be independent from the effect of 5-
HT2CR antagonism on early reversal learning, as it did not
occur following central microinfusions of the drug. Previous
studies of the 5-HT2CR in reversal learning using a variety of
paradigms have reported inconsistent results on late errors
(Boulougouris et al. 2008; Boulougouris and Robbins 2010;
Nilsson et al. 2012; Pennanen et al. 2013; Nilsson et al. 2013).
Nevertheless, it is clear that any of the possible ‘cognitive-
enhancing’ effects of the 5-HT2CR antagonist when systemi-
cally administered have to be interpreted in the context of
additional possible impairments, which may even lead to
overall deficits. The interesting issue is how this additional,
detrimental effect may arise. Chudasama and Robbins (2003)
found that there were at least two influences on the overall
attainment of successful reversal performance, an inhibitory
action on perseverative responding mediated by the rodent
lateral OFC and a separate effect on new associative learning
mediated by the medial PFC. Thus, it is possible that the 5-
HT2CR antagonist has dissociable effects on the OFC and
medial PFC, impairing the function of the latter. Clearly, sys-
temic administration of the antagonist would affect both re-
gions to produce these opposed effects on reversal-learning
performance. This could be approached in future experiments
by investigating reversal learning after 5-HT2CR blockade in
the medial PFC through SB 242084 microinfusions.
An alternative possibility is that the 5-HT2CR antagonist
exerts its behavioural effects on reversal-learning performance
indirectly through other actions. SB 242084 has previously
been shown to exacerbate premature, ‘impulsive’ responding,
for example in the 5-choice serial reaction time task (5-CSRT
T; Fletcher et al. 2007) even after profound 5-HT depletion
(Winstanley et al. 2004). Thus, it was previously proposed
that 5-HT2CR antagonism has opposite effects on compulsive
behaviour in the form of reversal learning and impulsive be-
haviour (Robbins and Crockett 2010). However, it is also
possible that these apparently contrasting effects to improve
early reversal learning and also impair late reversal perfor-
mance all arise as a consequence of the enhanced impulsivity
produced by the 5-HT2CR antagonist. Thus, elevated impul-
sivity could interfere with efficient choice behaviour by caus-
ing rapid, random, responding that increases late errors to
criterion. This interpretation is supported by the observation
that in addition to the increased errors responding following
systemic SB 242084 administration is also faster in terms of
both response latencies and pellet retrieval times. As well as
indicating possible impulsivity, these additional behavioural
effects might reflect motivational influences, for example, on
feeding at the level of the hypothalamus (Heisler et al. 2003).
It should also be considered that a similar effect on
impulsivity/motivation may account for the early improve-
ment in reversal learning. Thus, for example, if a tendency
to impulsive behaviour interferes with perseverative
responding, this may indirectly lead to an elimination of early
errors. However, against this interpretation are the observa-
tions that (i) although systemic SB 242084 consistently speed-
ed responding, it had no detrimental effect on initial discrim-
ination learning prior to reversal and (ii) inspection of discrim-
ination performance during early reversal (the initial 20 trials)
fails to show any immediate ‘beneficial’ effect of systemic SB
242084 and (iii) speeded responding, i.e. reduced response
latencies, was not observed after central administration of
SB 242084 despite its cognitive-enhancing effect.
Towards a reversal-learning test battery for rodents
We here report the development of two novel touchscreen
reversal tasks for the rat: a 3-stimulus paradigm that allows
the selective investigation of stimulus-perseveration during
reversal and a 2-stimulus serial reversal paradigm that allows
within-subject systemic and local pharmacological investiga-
tions. These two paradigms will be useful in different exper-
imental contexts or, as here, in conjunction.
The addition of a third stimulus to the discrimination task
stems from previous work in vervet monkeys (Jentsch et al.
2002) and allows the separate investigation of stimulus-
perseveration errors towards the previous CS+ and errors of
an explorative or general nature towards the unchanged, ‘con-
stant’ CS−. This approach may be particularly valuable when
pharmacological or genetic manipulations can be expected to
involve or affect inflexible responses to a stimulus that was
previously rewarded, such as after 5-HT depletion of the OFC
4028 Psychopharmacology (2015) 232:4017–4031
(Clarke et al. 2007) or perseveration induced by cocaine
(Jentsch et al. 2002).
The serial reversal paradigm, in contrast, was developed to
study the neuropharmacology of reversal learning using local
drug micro-infusions. In previously established visual dis-
crimination protocols, rodents require a large number of ses-
sions to reach criterion on visual reversal learning in the
touchscreen setting (Mar et al. 2013), making local infusions
throughout the reversal phase difficult. This obstacle to neu-
ropharmacological investigations was previously addressed
by micro-infusions on a subset of sessions, i.e. during early,
intermediate and late stages (Brigman et al. 2013). Here, we
instead developed a paradigm that allows the animals to reach
criterion in a brief period of time (typically three sessions) and
demonstrate that the optimised protocol robustly produces
perseverative responding across multiple reversals.
Importantly, performance on this paradigm engages the lateral
OFC; previous serial reversal paradigms using various modal-
ities have yielded inconsistent results, with lesions producing
impaired performance (Rygula et al. 2010), no effect
(Boulougouris and Robbins 2009) or either improved or im-
paired performance depending on the length of training be-
tween reversals (Riceberg and Shapiro 2012).
Conclusion
The present, cross-site study has shown dose-dependent im-
provements in early reversal learning produced by the 5-
HT2CR antagonist SB 242084 either following systemic or
central OFC administration which may have translational rel-
evance to reversal-learning impairments associated with neu-
ropsychiatric disorders such as schizophrenia or OCD.
However, we have additionally shown that systemic (but not
central) administration of the drug leads to additional effects
including speeded responding and impaired overall reversal
performance, thus highlighting potential problems in its clin-
ical utility.
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